Table of Contents Author Guidelines Submit a Manuscript
Experimental Diabetes Research
Volume 2007, Article ID 52487, 8 pages
http://dx.doi.org/10.1155/2007/52487
Review Article

Pharmacotherapies for Diabetic Retinopathy: Present and Future

1Bascom Palmer Eye Institute, Retina Center at Naples, 311 9th Street North, Naples, FL 34102, USA
2Bascom Palmer Eye Institute, 900 NW 17th Street, Miami, FL 33136, USA

Received 14 January 2007; Accepted 22 March 2007

Academic Editor: Subrata Chakrabarti

Copyright © 2007 Stephen G. Schwartz and Harry W. Flynn Jr. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. The Eye Diseases Prevalence Research Group, “Causes and prevalence of visual impairment among adults in the United States,” Archives of Ophthalmology, vol. 122, no. 4, pp. 477–485, 2004. View at Publisher · View at Google Scholar
  2. The Diabetes Control and Complications Trial Research Group, “The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus,” New England Journal of Medicine, vol. 329, no. 14, pp. 977–986, 1993. View at Publisher · View at Google Scholar
  3. UK Prospective Diabetes Study Group, “Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33),” The Lancet, vol. 352, no. 9131, pp. 837–853, 1998. View at Publisher · View at Google Scholar
  4. Early Treatment Diabetic Retinopathy Study Research Group, “Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1,” Archives of Ophthalmology, vol. 103, no. 12, pp. 1796–1806, 1985. View at Google Scholar
  5. Early Treatment Diabetic Retinpathy Study Research Group, “Early photocoagulation for diabetic retinopathy: ETDRS report number 9,” Ophthalmology, vol. 98, 5, pp. 766–785, 1991. View at Google Scholar
  6. M. Nauck, G. Karakiulakis, A. P. Perruchoud, E. Papakonstantinou, and M. Roth, “Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells,” European Journal of Pharmacology, vol. 341, no. 2-3, pp. 309–315, 1998. View at Publisher · View at Google Scholar
  7. M. Nauck, M. Roth, M. Tamm et al., “Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids,” American Journal of Respiratory Cell and Molecular Biology, vol. 16, no. 4, pp. 398–406, 1997. View at Google Scholar
  8. B. W. McCuen II, M. Bessler, Y. Tano, D. Chandler, and R. Machemer, “The lack of toxicity of intravitreally administered triamcinolone acetonide,” American Journal of Ophthalmology, vol. 91, no. 6, pp. 785–788, 1981. View at Google Scholar
  9. A. Martidis, J. S. Duker, P. B. Greenberg et al., “Intravitreal triamcinolone for refractory diabetic macular edema,” Ophthalmology, vol. 109, no. 5, pp. 920–927, 2002. View at Publisher · View at Google Scholar
  10. J. B. Jonas, I. Kreissig, A. Sofker, and R. F. Degenring, “Intravitreal injection of triamcinolone for diffuse diabetic macular edema,” Archives of Ophthalmology, vol. 121, no. 1, pp. 57–61, 2003. View at Google Scholar
  11. J. J. Chieh, D. B. Roth, M. Liu et al., “Intravitreal triamcinolone acetonide for diabetic macular edema,” Retina, vol. 25, no. 7, pp. 828–834, 2005. View at Publisher · View at Google Scholar
  12. M. C. Gillies, F. K. P. Sutter, J. M. Simpson, J. Larsson, H. Ali, and M. Zhu, “Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial,” Ophthalmology, vol. 113, no. 9, pp. 1533–1538, 2006. View at Publisher · View at Google Scholar
  13. D. S. Lam, C. K. Chan, S. Mohamed et al., “A prospective randomised trial of different doses of intravitreal triamcinolone for diabetic macular oedema,” British Journal of Ophthalmology, vol. 91, no. 2, pp. 199–203, 2007. View at Publisher · View at Google Scholar
  14. F. Bandello, A. Polito, D. R. Pognuz, P. Monaco, A. Dimastrogiovanni, and J. Paissios, “Triamcinolone as adjunctive treatment to laser panretinal photocoagulation for proliferative diabetic retinopathy,” Archives of Ophthalmology, vol. 124, no. 5, pp. 643–650, 2006. View at Publisher · View at Google Scholar
  15. D. N. Zacks and M. W. Johnson, “Combined intravitreal injection of triamcinolone acetonide and panretinal photocoagulation for concomitant diabetic macular edema and proliferative diabetic retinopathy,” Retina, vol. 25, no. 2, pp. 135–140, 2005. View at Publisher · View at Google Scholar
  16. P. A. Quiram, C. R. Gonzales, and S. D. Schwartz, “Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide,” American Journal of Ophthalmology, vol. 141, no. 3, pp. 580–582, 2006. View at Publisher · View at Google Scholar
  17. S. Kaushik, V. Gupta, A. Gupta, M. R. Dogra, and R. Singh, “Intractable glaucoma following intravitreal triamcinolone in central retinal vein occlusion,” American Journal of Ophthalmology, vol. 137, no. 4, pp. 758–760, 2004. View at Publisher · View at Google Scholar
  18. F. Viola, F. Morescalchi, and G. Staurenghi, “Argon laser trabeculoplasty for intractable glaucoma following intravitreal triamcinolone,” Archives of Ophthalmology, vol. 124, no. 1, pp. 133–134, 2006. View at Publisher · View at Google Scholar
  19. L. M. Smithen, M. D. Ober, L. Maranan, and R. F. Spaide, “Intravitreal triamcinolone acetonide and intraocular pressure,” American Journal of Ophthalmology, vol. 138, no. 5, pp. 740–743, 2004. View at Publisher · View at Google Scholar
  20. J. T. Thompson, “Cataract formation and other complications of intravitreal triamcinolone for macular edema,” American Journal of Ophthalmology, vol. 141, no. 4, pp. 629–637, 2006. View at Publisher · View at Google Scholar
  21. A. C. Westfall, A. Osborn, D. Kuhl, M. S. Benz, W. F. Mieler, and E. R. Holz, “Acute endophthalmitis incidence: intravitreal triamcinolone,” Archives of Ophthalmology, vol. 123, no. 8, pp. 1075–1077, 2005. View at Publisher · View at Google Scholar
  22. D. M. Moshfeghi, P. K. Kaiser, I. U. Scott et al., “Acute endophthalmitis following intravitreal triamcinolone acetonide injection,” American Journal of Ophthalmology, vol. 136, no. 5, pp. 791–796, 2003. View at Publisher · View at Google Scholar
  23. M. Tunc, H. I. Onder, and M. Kaya, “Posterior sub-Tenon's capsule triamcinolone injection combined with focal laser photocoagulation for diabetic macular edema,” Ophthalmology, vol. 112, no. 6, pp. 1086–1091, 2005. View at Publisher · View at Google Scholar
  24. S. J. Bakri and P. K. Kaiser, “Posterior sub-Tenon triamcinolone acetonide for refractory diabetic macular edema,” American Journal of Ophthalmology, vol. 139, no. 2, pp. 290–294, 2005. View at Publisher · View at Google Scholar
  25. J. A. Cardillo, L. A. S. Melo Jr., R. A. Costa et al., “Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema,” Ophthalmology, vol. 112, no. 9, pp. 1557–1563, 2005. View at Publisher · View at Google Scholar
  26. M. A. Bonini-Filho, R. Jorge, J. C. Barbosa, D. Calucci, J. A. Cardillo, and R. A. Costa, “Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: a randomized clinical trial,” Investigative Ophthalmology and Visual Science, vol. 46, no. 10, pp. 3845–3849, 2005. View at Publisher · View at Google Scholar
  27. Diabetic Retinopathy Clinical Research Network, E. Chew, S. Strauber, R. Beck et al., “Randomized trial of peribulbar triamcinolone acetonide with and without focal photocoagulation for mild diabetic macular edema: a pilot study,” American Journal of Ophthalmology, vol. 114, no. 6, pp. 1190–1196, 2007. View at Google Scholar
  28. G. J. Jaffe, D. Martin, D. Callanan, P. A. Pearson, B. Levy, and T. Comstock, “Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study,” Ophthalmology, vol. 113, no. 6, pp. 1020–1027, 2006. View at Publisher · View at Google Scholar
  29. “Fluocinolone acetonide ophthalmic - Bausch & Lomb: fluocinolone acetonide envision TD implant,” Drugs in R and D, vol. 6, no. 2, pp. 116–119, 2005. View at Publisher · View at Google Scholar
  30. B. D. Kuppermann, M. S. Blumenkranz, J. A. Haller et al., “Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema,” Archives of Ophthalmology, vol. 125, no. 3, pp. 309–317, 2007. View at Publisher · View at Google Scholar
  31. L. P. Aiello, S.-E. Bursell, A. Clermont et al., “Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective ß-isoform-selective inhibitor,” Diabetes, vol. 46, no. 9, pp. 1473–1480, 1997. View at Publisher · View at Google Scholar
  32. S. A. Vinores, A. I. Youssri, J. D. Luna et al., “Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease,” Histology and Histopathology, vol. 12, no. 1, pp. 99–109, 1997. View at Google Scholar
  33. A. P. Adamis, J. W. Miller, M.-T. Bernal et al., “Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy,” American Journal of Ophthalmology, vol. 118, no. 4, pp. 445–450, 1994. View at Google Scholar
  34. L. P. Aiello, R. L. Avery, P. G. Arrigg et al., “Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders,” New England Journal of Medicine, vol. 331, no. 22, pp. 1480–1487, 1994. View at Publisher · View at Google Scholar
  35. N. Ferrara, K. A. Houck, L. B. Jakeman, J. Winer, and D. W. Leung, “The vascular endothelial growth factor family of polypeptides,” Journal of Cellular Biochemistry, vol. 47, no. 3, pp. 211–218, 1991. View at Publisher · View at Google Scholar
  36. E. S. Gragoudas, A. P. Adamis, E. T. Cunningham Jr., M. Feinsod, and D. R. Guyer, “Pegaptanib for neovascular age-related macular degeneration,” New England Journal of Medicine, vol. 351, no. 27, pp. 2805–2816, 2004. View at Publisher · View at Google Scholar
  37. E. T. Cunningham Jr., A. P. Adamis, M. Altaweel et al., “A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema,” Ophthalmology, vol. 112, no. 10, pp. 1747–1757, 2005. View at Publisher · View at Google Scholar
  38. A. P. Adamis, M. Altaweel, N. M. Bressler et al., “Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals,” Ophthalmology, vol. 113, no. 1, pp. 23–28, 2006. View at Publisher · View at Google Scholar
  39. R. F. Spaide and Y. L. Fisher, “Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage,” Retina, vol. 26, no. 3, pp. 275–278, 2006. View at Publisher · View at Google Scholar
  40. R. Jorge, R. A. Costa, D. Calucci, L. P. Cintra, and I. U. Scott, “Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study),” Retina, vol. 26, no. 9, pp. 1006–1013, 2006. View at Publisher · View at Google Scholar
  41. R. L. Avery, J. Pearlman, D. J. Pieramici et al., “Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy,” Ophthalmology, vol. 113, no. 10, pp. 1695–1705.e6, 2006. View at Publisher · View at Google Scholar
  42. D. W. Chun, J. S. Heier, T. M. Topping, J. S. Duker, and J. M. Bankert, “A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema,” Ophthalmology, vol. 113, no. 10, pp. 1706–1712, 2006. View at Publisher · View at Google Scholar
  43. Q. D. Nguyen, S. Tatlipinar, S. M. Shah et al., “Vascular endothelial growth factor is a critical stimulus for diabetic macular edema,” American Journal of Ophthalmology, vol. 142, no. 6, pp. 961–969.e4, 2006. View at Publisher · View at Google Scholar
  44. The PKC-DRS Study Group, “The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the protein kinase C β inhibitor diabetic retinopathy study (PKC-DRS) multicenter randomized clinical trial,” Diabetes, vol. 54, no. 7, pp. 2188–2197, 2005. View at Publisher · View at Google Scholar
  45. PKC-DRS2 Group, “Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy,” Ophthalmology, vol. 113, no. 12, pp. 2221–2230, 2006. View at Publisher · View at Google Scholar
  46. The PKC-DMES Study Group, “Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial,” Archives of Ophthalmology, vol. 125, no. 3, pp. 318–324, 2007. View at Publisher · View at Google Scholar
  47. C. Strøm, B. Sander, K. Klemp, L. P. Aiello, H. Lund-Andersen, and M. Larsen, “Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema,” Investigative Ophthalmology and Visual Science, vol. 46, no. 10, pp. 3855–3858, 2005. View at Publisher · View at Google Scholar
  48. B. D. Kuppermann, E. L. Thomas, M. D. de Smet, L. R. Grillone, and Vitrase for Vitreous Hemorrhage Study Groups, “Pooled efficacy results from two multinational randomized controlled clinical trials of a single intravitreous injection of highly purified ovine hyaluronidase (Avastin®) for the management of vitreous hemorrhage,” American Journal of Ophthalmology, vol. 140, no. 4, pp. 573–584, 2005. View at Publisher · View at Google Scholar
  49. J. C. Yang, L. Haworth, R. M. Sherry et al., “A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer,” New England Journal of Medicine, vol. 349, no. 5, pp. 427–434, 2003. View at Publisher · View at Google Scholar
  50. S. Michels, P. J. Rosenfeld, C. A. Puliafito, E. N. Marcus, and A. S. Venkatraman, “Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study,” Ophthalmology, vol. 112, no. 6, pp. 1035–1047, 2005. View at Publisher · View at Google Scholar
  51. P. J. Rosenfeld, A. A. Moshfeghi, and C. A. Puliafito, “Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin®) for neovascular age-related macular degeneration,” Ophthalmic Surgery Lasers and Imaging, vol. 36, no. 4, pp. 331–335, 2005. View at Google Scholar
  52. P. J. Rosenfeld, A. E. Fung, and C. A. Puliafito, “Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin®) for macular edema from central retinal vein occlusion,” Ophthalmic Surgery Lasers and Imaging, vol. 36, no. 4, pp. 336–339, 2005. View at Google Scholar
  53. R. L. Avery, “Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment,” Retina, vol. 26, no. 3, pp. 352–354, 2006. View at Publisher · View at Google Scholar
  54. S. G. Schwartz, M. Hickey, and C. A. Puliafito, “Bilateral CRAO and CRVO from thrombotic thrombocytopenic purpura: OCT findings and treatment with triamcinolone acetonide and bevacizumab,” Ophthalmic Surgery Lasers and Imaging, vol. 37, no. 5, pp. 420–422, 2006. View at Google Scholar
  55. J. O. Mason III, M. A. Albert Jr., and R. Vail, “Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema,” Retina, vol. 26, no. 3, pp. 356–357, 2006. View at Publisher · View at Google Scholar
  56. C. Haritoglou, D. Kook, A. Neubauer et al., “Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema,” Retina, vol. 26, no. 9, pp. 999–1005, 2006. View at Publisher · View at Google Scholar
  57. P. J. Rosenfeld, D. M. Brown, J. S. Heier et al., “Ranibizumab for neovascular age-related macular degeneration,” New England Journal of Medicine, vol. 355, no. 14, pp. 1419–1431, 2006. View at Publisher · View at Google Scholar
  58. D. M. Brown, P. K. Kaiser, M. Michels et al., “Ranibizumab versus verteporfin for neovascular age-related macular degeneration,” New England Journal of Medicine, vol. 355, no. 14, pp. 1432–1444, 2006. View at Publisher · View at Google Scholar
  59. J. S. Heier, A. N. Antoszyk, P. R. Pavan et al., “Ranibizumab for treatment of neovascular age-related macular degeneration. A phase I/II multicenter, controlled, multidose study,” Ophthalmology, vol. 113, no. 4, pp. 633–642.e4, 2006. View at Publisher · View at Google Scholar
  60. A. E. Fung, P. J. Rosenfeld, and E. Reichel, “The international intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide,” British Journal of Ophthalmology, vol. 90, no. 11, pp. 1344–1349, 2006. View at Publisher · View at Google Scholar
  61. L. P. Aiello, S.-E. Bursell, A. Clermont et al., “Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective ß-isoform-selective inhibitor,” Diabetes, vol. 46, no. 9, pp. 1473–1480, 1997. View at Publisher · View at Google Scholar
  62. B. D. Kuppermann, E. L. Thomas, M. D. de Smet, L. R. Grillone, and Vitrase for Vitreous Hemorrhage Study Groups, “Safety results of two phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Avastin®) for the management of vitreous hemorrhage,” American Journal of Ophthalmology, vol. 140, no. 4, pp. 585.e1–585.e15, 2005. View at Publisher · View at Google Scholar